EUCTR2018-003089-14-GB进行中（未招募）1 期
Azathioprine Immunosuppression and Disease Modification in Parkinson’s Disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial - AZA-PD
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge0 个研究点目标入组 60 人开始时间: 2019年10月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Aged 50 years or over
- •Be a fluent English speaker
- •Have a diagnosis of PD according to UKPDS Brain Bank Criteria
- •Have a disease duration of <3 years
- •Have a probability of poor outcome (postural instability/dementia/death) at 5 years from diagnosis =50% [28]
- •Have adequate organ and marrow function, as defined below (measured within 42 days of first dose of trial medication):
- •o Haemoglobin = 110 g/L
- •o Platelet count = 130 x 109/L
- •o Neutrophil count = 1.5 x 109/L
- •o Renal Function- Creatinine clearance =50mL/min
- •o Hepatic function- Alanine aminotransferase (ALT) =2 times the institutional upper limit of normal (ULN) and total bilirubin =2 times the ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •The presence of any of the following will preclude participant inclusion:
- •Any use of immunomodulatory drugs such as azathioprine, mycophenolate, methotrexate, ciclosporin, cyclophosphamide within the last 12 months
- •Any previous use of rituximab or alemtuzumab
- •Previous treatment with corticosteroids for greater than 2 weeks, or any steroid use in the last 3 months
- •Regular use of non-steroidal anti-inflammatory drugs including aspirin>75mg, naproxen, ibuprofen, meloxicam on more than 2 days per week.
- •Known inflammatory or autoimmune disease
- •Chronic or latent infection
- •Active infection requiring the use of parenteral antimicrobial agents within 2 months prior to the first dose of study treatment.
- •Skin malignancy or solid organ malignancy within the last 5 years.
- •Current or previous haematological malignancy
- •Positive test for HIV or hepatitis
- •The inability to take or swallow oral medication
- •Dementia according to Movement Disorder Society dementia criteria
- •Thiopurine methyltransferase (TPMT) deficiency <10 pmol/h/mg Hb
- •Lack of immunity to VZV
- •Negative EBV IgG
- •Chronic liver disease
- •Renal impairment - creatinine clearance <50mL/min
- •Concomitant use of allopurinol (increases risk of myelotoxicity)
- •Any concurrent medical or psychiatric condition or disease (e.g. active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.
- •Receipt of live, attenuated vaccine within the last 30 days. Note: enrolled patients should not receive live, attenuated vaccine while receiving azathioprine nor within 30 days of last dose of azathioprine
- ••Women of childbearing potential. Female patients must be surgically sterile or be postmenopausal.
- •oPostmenopausal is defined as spontaneous cessation of regular menses for at least 12 consecutive months or follicle-stimulating hormone (FSH) blood levels in the testing laboratory’s respective postmenopausal range with no alternative pathological or physiological cause.
- •Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy and for 6 months after completion of trial drug
- •Known hypersensitivity to azathioprine or its excipients
- •Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before treatment protocol registration or is currently enrolled in an interventional investigational study.
研究者
相似试验
尚未招募
2 期
Improving Tuberculous Meningitis Care: Testing the Safety and Effectiveness of Azathioprine in Managing Paradoxical Reactions - A Patient-Focused StudyCTRI/2023/12/060448Department of Neurology King George Medical University
已完成
2 期
A trial investigating whether suppressing the immune system with azathioprine slows the progression of Parkinson’s diseaseParkinson's diseaseNervous System DiseasesParkinson diseaseISRCTN14616801Cambridge University Hospitals NHS Foundation Trust67
已完成
2 期
Examination of the mizoribine and azathioprine combination immunosuppressive therapy in primary sclerosing cholangitisK830PSCPrimary sclerosing cholangitisJPRN-jRCTs051180120Tajiri Hitoshi1
尚未招募
3 期
Azathioprine effect in severe asthmatic patientsIRCT20231219060463N1Ahvaz University of Medical Sciences40
已完成
不适用
Azathioprine as an adjuvant therapy in severe Graves’ disease: A new perspectiveNutritional, Metabolic, EndocrinePACTR201912487382180Alexandria University163